Selected Life Science Stocks Continue to Outperform the Market: Up 30% and More
Here is a portfolio summary of my picks and current assessment prior to the so-called "sell-off" zone May 8-24.
We are still cautious on adding new biotech positions except stocks that were mentioned last month (see Alkermes ALKS, Array ARRY and Achillion ACHN). Many biotech MO stocks are well off their highs. All positions remain as HOLDS unless you want to raise a little cash. Albany Molecular (AMRI) is up 5%, a value play (PS 1.76) as more investors have discovered the CRO sector because more biotech companies are outsourcing R&D. AMRI is up more than 100% YTD and was added to the Portfolio on 2/10/11 at $4.68.
Technicals rule at this point near the IBB top at $176.
Here is a brief summary of our picks:
Alexion (NASDAQ:ALXN) strong hold but way off top of $119.54.
Amgen (NASDAQ:AMGN) strong hold.
Biogen (NASDAQ:BIIB) strong hold.
Cubist (CBST) strong hold.
Exelixis (NASDAQ:EXEL) weak for trades only.
Immunogen (NASDAQ:IMGN) strong hold.
Optimer (NASDAQ:OPTR) strong hold.
Pharmacyclics (NASDAQ:PCYC) off all time high of $95.85. MO stock weak technically.
Regeneron (NASDAQ:REGN) high flyer MO stock hit with profit taking after blow-off last week.
Seattle Genetics (NASDAQ:SGEN) strong hold.
Viropharma (VPHM) strong hold.
Some Big Winners in Diagnostics
Rayno Diagnostics and Tools-Awaiting Q1 Results
Many Rayno Diagnostics and Tools stocks have made new highs recently despite the sector being less frothy than biopharmaceuticals. These stocks are more pinned to financial results and dependent on a steady stream of new products. Important themes are genomics, molecular diagnostics, companion diagnostics and novel assays for infectious diseases like Flu and HCV. Recently we added Genomic Health (GHDX) a play in personalized medicine for cancer at $28.5 and Hologic (NASDAQ:HOLX) at $21.60.
Hologic, a broad -based diagnostics and women's health play has been a laggard and is selling off 4% today after the earnings release. Hologic results include the acquired GenProbe with Q2 revenues of $160.5M. The fiscal Q2 net loss was $51.1M or $0.19 per share. Revenue guidance was cut to $2.53B-2..55B from $2.61-$2.64B. Women's health and imaging sales were mixed with Thin Prep Sales weak, so it appears that the GenProbe acquisition was the right move. We were a bit early into this stock but would still bet on a turnaround with the PE of 11.41 and a P/S of 2.56. This also has been a volatile stock with a lot of selling going on lately so we need to hold near the $20 level with some downside to $19.
Here is a quick review of our portfolio:
Abaxis (ABAX) big winner,strong hold, buy on weakness, off top of $48.
Alere (NYSE:ALR) reiterated buy at $19 after collapse of stock. Value play and turnaround now at $27.
Cardiovascular System (NASDAQ:CSII) strong hold for Company focused in minimally invasive cardiovascular disease.
Cepheid (CPHD) top molecular diagnostics play, strong hold, despite valuation.
Exact Sciences (NASDAQ:EXAS) long term play for molecular test for colon cancer.
Illumina (ILMN) big winner,up 11 pts since early April. Gotta be in this premier sequencing play, buy on weakness.
Neogen (NASDAQ:NEOG) strong hold at new highs at $52. Niche products for food and animal safety.
Qiagen (NASDAQ:QGEN) turnaround molecular diagnostic play has been disappointing. Hold is only for the patient.
Quidel (NASDAQ:QDEL) big winner,off its highs near $25. Strong hold.
Response Genetics (NASDAQ:RGDX) turnaround play. A wait and see hold. Tightly held.
For a complete summary of key financial metrics se our March 21 posting that summarizes 2012 Results.